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Eurasian wild boar (Sus scrofa) is the main wildlife reservoir for tuberculosis (TB) in Iberia. This review summarizes the current
knowledge on wild boar vaccination including aspects of bait design, delivery and field deployment success; wild boar response to
vaccination with Bacillus Calmette-Gue´rin (BCG) and inactivated Mycobacterium bovis; and wild boar vaccination biosafety
issues as well as prospects on future research. Oral vaccination with BCG in captive wild boar has shown to be safe with
significant levels of protection against challenge with virulentM. bovis. An oral vaccination with a new heat-killedM. bovis vaccine
conferred a protection similar to BCG. The study of host-pathogen interactions identified biomarkers of resistance/susceptibility
to tuberculosis in wild boar such as complement component 3 (C3) and methylmalonyl coenzyme A mutase (MUT) that were
used for vaccine development. Finally, specific delivery systems were developed for bait-containing vaccines to target diﬀerent age
groups. Ongoing research includes laboratory experiments combining live and heat-killed vaccines and the first field trial for TB
control in wild boar.
1. Introduction
Total eradication of an infectious agent shared between wild
and domestic animals is almost impossible if a native wildlife
host is able to serve as a natural reservoir of the pathogen [1–
3]. Tuberculosis (TB) is a chronic disease caused by infection
withMycobacterium bovis and closely related members of the
Mycobacterium tuberculosis complex (MTC). TB aﬀects not
only cattle but also a range of other livestock, companion
animals, and wild animals. Humans are also susceptible;
hence control of the risks of zoonotic infection is a driver for
disease control in animal hosts. As TB prevalence has been
reduced in livestock, the relative epidemiological and socio-
economic importance of wildlife reservoirs has increased
and there is a corresponding need for disease management
strategies to reflect this eﬀect [4].
Disease control through vaccination of wildlife reser-
voirs has advantages over other approaches. When dealing
with disease maintenance by native wildlife, vaccination—
as opposed to culling—is a nondestructive method of
controlling disease that is more acceptable to the public [5,
6]. The primary goal of a wildlife vaccine would be to reduce
the prevalence of infection in the wildlife reservoir or to
change the expression of the disease and limit the rate of M.
bovis excretion [7]. Indeed, vaccination is nowadays explored
as an option for TB control in all major wildlife reservoir
hosts such as the brushtail possum (Trichosurus vulpecula)
in New Zealand, Eurasian badger (Meles meles) the United
Kingdom and the Republic of Ireland, and white-tailed deer
(Odocoileus virginianus) in the USA, among others [8].
In Mediterranean habitats of the south-western Iberian
Peninsula, the abundant and widespread native Eurasian
wild boar (Sus scofa) is an important driver in M. bovis
epidemiology [9], thus the need for TB control in this
species. Since uninfected 2–4-month-old wild boar piglets
are the preferred age class for vaccination [10], an oral
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delivery system that targets piglets is needed for field
application of oral tuberculosis vaccines in wild boar. After
briefly introducing the role of the wild boar in tuberculosis
(TB) epidemiology and the options for TB control, this
review summarizes the current knowledge on wild boar
vaccination including aspects of bait design, delivery, and
field deployment success; wild boar response to vaccination
with BCG and inactivated Mycobacterium bovis; wild boar
vaccination biosafety issues as well as prospects on future
research.
2. Tuberculosis in EurasianWild Boar
The Eurasian wild boar is the ancestor of the domestic pig.
It is native to Eurasia and the north of Africa and has
been introduced, pure or crossbred, to many other regions
worldwide. TB is one of the main infections shared between
wild boar and other wild and domestic animals [4]. TB
has a complex epidemiology involving multiple hosts and
is influenced by climate, habitat, and management factors.
Consequently, the role of wild and domestic hosts in TB
epidemiology varies among regions [11].
Despite the success of compulsory test and slaughter
campaigns in cattle, bovine TB (bTB) is still present in
the Iberian Peninsula, and the role of wildlife reservoirs
is increasingly recognized [4, 11, 12]. In Mediterranean
habitats of southern Portugal and south-western Spain, MTC
transmission occurs among three wild ungulate species, wild
boar, red deer (Cervus elaphus), as well as fallow deer (Dama
dama), cattle, and to a lesser extent other domestic and wild
animals such as goats, pigs, and Eurasian badgers [4, 13, 14].
Nevertheless, there is consensus in defining the wild
boar as the single most important TB reservoir host in this
region [9, 13, 15–17]. Extremely high densities and high
contact rates within social groups and at waterholes or focal
food sources might contribute to the high TB prevalence,
often over 40% prevalence [12, 13, 16, 18–20]. Wild boar
experience higher levels of exposure than deer [18] and are
at greater infection risk as a result of feeding on tuberculous
carrion [13]. Finally, wild boar are more likely than deer
to push their way under fences, facilitating contact with
livestock [12]. Work on TB time trends in Iberian wild
boar has shown a stable prevalence with local variability, as
well as an apparent expansion of the infection to new sites
[21]. Moreover, wild boar TB has already been described in
at least ten European countries (Bulgaria, Croatia, France,
Germany, Hungary, Italy, Portugal, Slovakia, Spain, and the
UK), and evidence as wildlife reservoirs is growing beyond
the peculiar high-density and intense-management systems
of south-central Iberia [4].
Naturally, MTC-infected wild boar show visible lesions
in over 80% of the cases and only microscopic lesions in
another 9% [22]. The distribution of lesions is generalized
in two thirds of the cases, meaning that they are evident
in more than one anatomic region. The mandibular lymph
node (mLN) is the most frequently aﬀected organ while large
generalized and lung lesions are more frequent among 1 to
2 year old subadults, which have the highest potential to
excrete mycobacteria and can die due to the disease [22].
Prevalence increases with age, < 6month-old piglets showing
a mean of 10% prevalence [15].
In contrast to wild boar, the role of feral pigs as MTC
reservoirs is questioned [23–25]. However, domestic pigs
and free-ranging Sus scrofa are MTC hosts in southwestern
Spain [26], the Mediterranean islands of Corsica, Sardinia
and Sicily [27–29], and the Hawaiian island of Molokai [30].
In Argentina, a wild-boar-derived M. bovis strain proved
more pathogenic than the reference cattle-derived strain in
a cattle challenge model [31]. Hence, the role of suids in the
maintenance of MTC deserves more attention worldwide.
3. Options for TB Control inWild Boar
The first requisite for any disease control in wildlife is
establishing a proper monitoring scheme [32]. Then, actions
towards disease control can be critically assessed. TB control
in wildlife reservoir hosts can eventually be achieved by dif-
ferent means, including (1) the improvement of biosecurity
and hygiene, (2) population control through random or
selective culling or through habitat management, and (3)
vaccination. Ideally, tools from all three fields should be
combined in an integrated control strategy.
In this context, wildlife vaccination to reduce MTC
infection prevalence emerges as a valuable alternative or
complementary tool in TB control [43]. Capturing wild
animals to vaccinate them individually is expensive, time
consuming, and diﬃcult [44]. Therefore, the most feasible
approach to deliver vaccines to wildlife is the use of oral baits.
Oral vaccination against rabies was the first successful
attempt to control a disease in wildlife through vaccination
[45]. Thus, oral bait vaccination has also been considered
for controlling other diseases such as classical swine fever in
wild boar in Europe [33, 46] or TB in several wildlife hosts
worldwide [47].
4. Bait Design, Selective Delivery, and Field
Deployment Success
The eﬀective and eﬃcient field vaccination of wildlife
requires the development of baits that are stable under field
conditions, safe for target and nontarget species as well as
the environment, and eﬀective in reaching the target species
[48–50]. A wide variety of baits have been developed in order
to deliver pharmaceuticals to wild species. Lipid-based baits
have been tested to deliver BCG vaccine against TB in wild
animal species that act as reservoirs hosts such as badgers in
United Kingdom and Republic of Ireland [44], possums in
New Zealand [51–53], and while-tailed deer in USA [54].
For free-ranging Sus scrofa, three diﬀerent baits have
been developed and used for the oral delivery of vaccines
and pharmaceuticals (Table 1). All of them are made with a
cereal-based matrix containing a capsule or blister to deliver
the vaccine or pharmaceutical. The palatable ingredients
used for the bait matrix composition stimulate chewing to
open the capsules contained in the baits and releasing their
content inside the oral cavity [36].
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Table 1: Characteristics of commercial, registered, or patented baits designed for the delivery of vaccines or pharmaceuticals to wild boar
and feral pigs. Disadvantages include particularly their suitability for vaccine delivery to piglets.
Bait Shape and size Use Advantages Disadvantages References
Riemser
Square shape
(4× 4× 1.5 cm)
Delivery of vaccines
against classical swine
fever in Europe
Resistant to
water and
moisture
Not resistant to warm
temperatures
Not completely consumed by <4.5
month-old wild boar piglets
[33–35]
IREC, Spain
Hemispherical shape
( Ø3.4× 1.6 cm;
Figures 1(a) and 1(b))
Delivery of vaccines
against Mycobacterium
bovis in Spain
Resistant to high
temperatures
Well accepted by
2–4 month-old
wild boar piglets
Not resistant to water and
moisture
[10, 36–
38]
PIGOUT
Cylindrical shape
(9× 5 cm)
Delivery of toxicants
or pharmaceuticals to
feral pigs in Australia
and USA
Resistant to high
temperatures
Large size would not be suitable
for piglets
[39–42]
For TB vaccination, wild boar piglets (rather than already
infected adults) are the main target [10]. If BCG was used,
accidental bait uptake by cattle needs to be avoided [55].
Hence, purpose-designed baits and oral delivery systems
selective for piglets are needed. The three baits developed
for free-ranging Sus scrofa have been found to be highly
attractive and readily ingested by animals [33, 36, 37, 39, 40].
However, both Spanish and PIGOUT baits have been found
to be not target-specific enough in those areas where other
wildlife species can also have access to the baits [10, 41, 42].
No data concerning target specificity of Riemser baits has
been published.
Field assessment of the proportion of target and nontar-
get individuals that consume baits is crucial to evaluate the
success of a baiting campaign. Therefore, marking agents are
incorporated into baits to enable identification of consuming
individuals [56]. Iophenoxic acid (α-ethyl-2-hydroxy-2,4,6-
triiodebenzenepropanoic acid) and its derivatives have been
used successfully to investigate baits and baiting strategies to
deliver orally vaccines, contraceptives, and toxicants [41, 57–
61], since they bind to protein in the blood plasma and
elevate the protein-bound iodine of animals which consume
them. So, these markers can be detected in the serum of
animals consuming IPA-marked baits for a long time after
their ingestion [62]. In the case of wild boar, Ballesteros
et al. [63] found that ethyl and propyl-iophenoxic acids could
be detected in animal serum up to 18 months after their
consumption when doses of 5 and 15 mg/kg were delivered.
Bait consumption rate and host specificity depend
directly on the delivery method employed [10, 55]. To
date, three delivery systems have been designed to allow
free-ranging Sus scrofa access to baits while preventing
bait consumption by nontarget species: the Boar-Operated-
System [64–66], the HogHopper [67, 68], and portable
selective wild boar piglet feeders of Spanish patent [37].
The BOS consists of a metal pole onto which a round
perforated base is attached. A metal cone with wide rim
slides up and down the pole and fully encloses the base onto
which the baits are placed. This system has been tested in
United Kingdom [66] and the United States [65] showing low
bait consumption by nontarget species. However, a possible
disadvantage to this system is its cost [65]. The Hog-Hopper
is a new box-shaped bait delivery device designed to allow
feral pigs to access poison baits in the station, and to restrict
other species (such as Australian native species and livestock)
from taking bait. The door of the device is easily raised
by feral pigs allowing them to feed on bait, but it excludes
nontarget species that lack the physical attributes to lift the
sliding door. Small rodents are also unable to access baits.
The device has the added benefit of preventing bait from
being exposed to rain, thereby preventing bait degradation
[67, 68]. Selective feeders were used by Ballesteros et al.
[37] in order to reduce bait consumption by nontarget
species in southern Spain. These triangular-shaped feeders
(side = 1m) consist of a 1-cm-∅ metal-grid cage with an
opening (15-cm wide) to allow only access of young wild
boar (Figure 1(c)). A green mesh that provides shade covers
the cage (Figure 1(d)). Although this system was found to be
highly selective for wild boar piglets [10], occasionally small
animals such as badgers can enter inside the feeders and have
access to the baits [37].
The success of vaccination programs is also determined
by the timing of bait delivery. For example, early summer
would be the best timing for TB vaccine bait delivery to
wild boar piglets in south-central Spain [10]. In addition,
bait consumption by wild boar or feral pigs is better if the
prebaiting period lasts longer (e.g., feeding corn weekly for
three weeks) so that animals get accustomed to feed in the
place where baits will be delivered [37, 69, 70]. Other factors
such as baiting and/or free-ranging Sus scrofa densities can
aﬀect bait consumption by target species [37]. Ballesteros
et al. [37] found marked-bait consumption by up to 73%
wild boar piglets at a bait density of 30 baits/km2 and using
one piglet feeder per 2 km2. These baiting densities were
lower than those used in previous studies in other countries
(e.g., 68 to 489 baits/km2 [41, 57]. Therefore, in future TB
vaccination experiments, it would be desirable to use higher
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Figure 1: (a) and (b) Baits developed to deliver vaccines to wild boar in Spain. They are composed of piglet feed, paraﬃn, sucrose and
cinnamon-truﬄe powder attractant. (c) Wild boar piglets consuming baits inside selective feeders. (d) Portable selective feeder used to
deliver baits to young wild boar.
baiting densities to target a higher percentage of the wild boar
population.
5. Tuberculosis Vaccines inWildlife
Live vaccines are believed to confer more protection against
mycobacterial infections than killed vaccines [71]. This is
the case of the attenuated live strain of M. bovis BCG [72],
which is currently the only vaccine approved for vaccination
of humans against TB [73, 74]. Since 1921, BCG has been
used worldwide and reports of adverse reactions arising from
the use of this vaccine have been relatively uncommon [75].
Also, BCG is the most widely used vaccine for TB control in
wildlife reservoirs. Experiments in controlled environments
have been carried out in several host species such as badgers
[76], brushtail possums [77], Cape buﬀalo (Syncerus caﬀer)
[78], white-tailed deer [54, 79], wild boar [38], and ferrets
(Mustela furo) [80]. In addition, recent reports on field
vaccination of badgers in the UK [81] and possums in New
Zealand [53] encourage the use of BCG for TB control in
wildlife. Additionally, due to its long and widespread use in
diﬀerent species, licensing BCG for field use in wild animals
is easier than licensing a newly developed vaccine [81, 82].
However, the use of BCG has some disadvantages,
including (1) its variable eﬃcacy in humans and cattle due to
diﬀerences among BCG vaccine strains, trial methodology,
and prior host sensitization to a variety of environmental
mycobacteria [71, 83–87], (2) the possibility to cause disease
or to infect nontarget individuals and cause interference with
TB diagnosis [88–92], and (3) its limited half life in the
environment and during vaccine preparation, shipment, or
storage [93].
The use of killed vaccines would eliminate the risk of
causing TB and should limit the likelihood of diagnostic
interference and make field vaccination protocols cheaper.
Several authors have found experimental evidence indicating
that nonviable bacilli are able to produce some degree of
protection to TB in guinea pigs [94–99], mice [100–103]
and dogs [104]. In wildlife, only limited information exists
regarding inactivated vaccines. Experiments with inactivated
vaccines have been conducted in deer, brushtail possums,
and recently in wild boar [105–107]. Deer were vaccinated
with two doses of heat-killed BCG (5 × 107 cfu) in an
oil adjuvant finding no protection against experimental
challenge with virulentM. bovis [105]. In brushtail possums,
the heat-inactivated M. vaccae was used to improve the
eﬀectiveness of live BCG to protect against bTB [106].
Recently, heat-inactivated M. bovis was found to confer
protection against TB similar to BCG to wild boar [107].
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6. Wild Boar Response to BCG Vaccination
The first results about wild boar response to BCG vaccination
were documented in 2009, after vaccinating seven animals by
the intramuscular route [108]. Later, a subsequent study by
Ballesteros et al. [38] analyzed wild boar responses to oral
BCG vaccination and challenge with a M. bovis field strain.
Purpose-designed oral baits were used for the experiment
[36]. The oropharyngeal route was found appropriate for
wild boar experimental infection since lesions recorded
resembled those of natural mycobacterial infections [109].
This research allowed defining the infection model and
a lesion scoring system for wild boar TB [38], while
further experiments increased the information on wild boar
response to BCG vaccination [107].
In captive wild boar, BCG has shown significant levels
of protection against challenge with a virulent M. bovis
field strain. Culture scores and lesion scores of orally BCG-
vaccinated wild boar were consistently lower in vaccinated
than in control nonvaccinated animals [38, 107]. In addition,
the reduction of the lesion and culture scores in the thoracic
organs has been between 67% and 90% as compared to
unvaccinated controls [107]. Vaccinated wild boar exposed
to low-or-medium doses of M. bovis (102 cfu or 104 cfu) by
the oropharyngeal route generally remain either uninfected
or develop only limited lesions [38].
Antibody responses of wild boar against M. bovis have
been detected reliably with specific serologic tests [21,
110, 111]. This enzyme-linked immunosorbent assay uses
M. bovis purified protein derivative (bPPD ELISA test).
Antibodies to bPPD increase only slightly and late after
challenge and correlate with the total lesion scores of
BCG vaccinated and M. bovis challenged wild boar [107].
Additionally, an innovative dual-path platform test (DPP
test) using MPB83 and CFP10/ESAT-6 antigens has also
been used to monitor antibody production in vaccination
experiments in captive wild boar [107, 111]. Also, IFN-
gamma production in response to bPPD has been detected
in both BCG vaccinated and unvaccinated wild boar afterM.
bovis challenge [107].
7. Wild Boar Response to Vaccination with
Heat-InactivatedM. bovis
Recently, a heat-killed M. bovis vaccine for oral and par-
enteral use was developed and tested in wild boar [107]. Each
oral dose contained 6 × 106 bacteria in 2mL of PBS, and
each parenteral dose contained the same number of bacteria
in 1mL Montanide ISA 50V (Seppic, Castres, France).
The first study incorporating this new inactivated vaccine
showed that oral or parenteral vaccination with heat-
inactivated M. bovis conferred a similar protection after
challenge when compared to oral vaccination with BCG,
and that the response of wild boar to both vaccines was
similar. Although a high challenge dose was used (106 cfu),
this vaccination protocol reduced the number and severity of
lesions and the infection burden, particularly in the thoracic
region [107].
The dynamics of antibody production, IFN-gamma
response, and gene expression were similar in oral BCG-
and inactivated M. bovis-vaccinated animals. Wild boar par-
enterally vaccinated with the inactivated vaccine responded
to the MPB83 antigen but not to bPPD immediately after
vaccination, suggesting potential use of these ELISAs to
distinguish between parenterally vaccinated and exposed
wild boar [107].
8. Wild Boar-Pathogen Interactions and
Protection against TB
The study of host-pathogen interactions allowed identifying
biomarkers of resistance/susceptibility to tuberculosis in wild
boar and using these biomarkers for vaccine development
[63, 107, 108, 112–115]. The expressions of some of
these genes such as complement component 3 (C3) and
methylmalonyl coenzyme A mutase (MUT) were shown to
correlate with resistance to natural M. bovis infection and
protection against M. bovis challenge in BCG-vaccinated
wild boar [9, 38, 107, 108, 116]. In these experiments, C3
and/or MUT mRNA levels were higher in nontuberculous
than in tuberculous adult wild boar naturally exposed to
mycobacterial infection, decreased after M. bovis infection
and increased with BCG vaccination, with higher mRNA
levels in protected animals [9, 38, 107, 108, 113, 114, 116,
117]. Additionally, MUT may be genetically associated with
resistance to tuberculosis in wild boar [113, 116, 117].
The mechanisms by which C3 and MUT expression
contributes to resistance to mycobacterial infection remain
unknown. The complement system has been shown to be
involved in mycobacterial pathogenesis and M. tuberculosis
activates the alternative pathway of complement and binds
C3 protein, resulting in enhanced phagocytosis by comple-
ment receptors (CR3) on human alveolar macrophages [118,
119]. A similar mechanismmay occur withM. bovis in which
C3 opsonophagocytosis of mycobacteria by macrophages
may result in the inhibition of host bactericidal responses
and pathogen survival [118]. Consequently, higher levels of
C3 in wild boar may allow increased binding of C3 to CR3 to
promote phagocytosis and eﬀective killing of bacteria, while
interfering with CR3-mediated opsonic and nonopsonic
phagocytosis of mycobacteria [114]. For MUT, a hypothesis
was recently discussed to suggest that host genetically
defined higher MUT expression levels result in lower serum
cholesterol concentration and tissue deposits that increase
the protective immune response to M. bovis, thus resulting
in resistance to tuberculosis and better response to BCG
vaccination [117].
The mechanism of protection from BCG vaccination
involves a reduction of the haematogenous spread of
mycobacteria from the site of primary infection. It protects
against the acute manifestations of the disease, and reduces
the lifelong risk of endogenous reactivation and dissemina-
tion associated with foci acquired from prior infection [120].
It is tempting to speculate that BCG protection in
wild boar would involve distinct systemic and mucosal
populations of eﬀector memory T cells. Immune genes with
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significant overexpression in nontuberculous than in tuber-
culous adult wild boar naturally exposed to mycobacterial
infection include RANTES (aka Chemokine (C-C motif)
ligand 5; CCL5), IFN-gamma, and IL4 [108]. The mRNA
levels of these genes also increased after parenteral and oral
BCG vaccination of wild boar [38, 108], thus suggesting
that IFN-gamma and activated RANTES-secreting CD8 (+)
and/or CD4 (+) T lymphocytes may be key players in BCG-
induced protective response in wild boar. However, although
it is generally recognized that humoral immunity is not
important for the control of tuberculosis [121], IL4-induced
antibody response against M. bovis may be important for
tuberculosis control in wild boar. IL4 overexpression in
nontuberculous and BCG-vaccinated wild boar suggests that
antibodies against mycobacterial proteins may be used for
disease surveillance and treatment monitoring in this species
[21, 107, 110, 111] and underline the existence of host-
specific responses to mycobacterial infection [122] as the
increase in IL4 levels correlates with disease severity in
humans [123] but not in wild boar.
Inactivated vaccines stimulate specific CD4 (+) cell
populations that recognize the antigen versus a live vaccine
that stimulates many T cell populations simultaneously.
While antibody and IFN-gamma responses increased after
vaccination in parentally BCG-vaccinated wild boar, in orally
BCG and inactivated M. bovis vaccinated wild boar, only
MUT mRNA levels correlated with protection [107]. These
results are diﬃcult to explain before further experiments
help to characterize the mechanism by which vaccination
with the inactivated vaccine protects against tuberculosis in
wild boar. Taken together, these results suggest diﬀerent pro-
tective mechanisms between parenteral and oral inactivated
mycobacterial vaccines and, at least for MUT, expression
levels could be a marker of protection against tuberculosis
and may be used to characterize host response to BCG
vaccination in wild boar.
9. Wild Boar Vaccination Biosafety Issues
Four main biosafety issues must be considered before
delivery of oral baits containing live vaccines such as BCG
to wild boar: (1) potential eﬀects of high vaccine doses
(e.g. ten times the normal dose) on wild boar health;
(2) potential survival of M. bovis BCG in vaccinated wild
boar; (3) potential excretion of M. bovis BCG by vaccinated
wild boar; (4) vaccine-containing bait uptake by nontarget
species, particularly by cattle.
Regarding point (1), it is highly important to determine
that high doses of vaccine do not aﬀect the animal’s health
since it is likely that few individuals can gain access to a high
number of baits during field vaccination campaigns. In the
case of wild boar, no adverse eﬀects that can be attributed
to the vaccine have been detected in vaccinated individuals
[38, 107, 108]. Moreover, wild boar treated with high vaccine
doses of up to 3.0 × 106 cfu did not show any adverse eﬀect
after BCG administration [38].
Concerning point (2), M. bovis BCG has never been
isolated from tissues of vaccinated wild boar, despite the
occasionally high doses used (the authors, unpublished
information). However, in other species, such as brushtail
possum and deer, BCG was isolated in tissues of oral BCG
vaccinated animals after necropsy [124, 125].
Regarding point (3), the potential of faeces from vac-
cinated wild boar to lead to the accidental exposure of
non-target species to BCG, shedding of BCG following bait
ingestion has been tested under laboratory conditions over a
period of seven days post vaccination. The analyses yielded
no BCG isolates (unpublished data). In other TB hosts, BCG
is detected in faeces only for a short period of time after
ingestion [52, 125].
Finally, point (4), it is necessary to consider the possi-
bility of bait consumption by nontarget species. Oral baits
developed by Ballesteros et al. [36] were found highly palat-
able to both wild and domestic animals [55]. This fact could
have negative eﬀects in areas where cattle and wild reservoirs
coexist since accidental consumption of BCG-containing
baits by cattle could interfere in the TB test and slaughter
campaigns. However, this risk can be reduced by using
deployment strategies that assure that only target species gain
access to bait such as selective feeders [10, 37]. Moreover, the
scheduled preliminary field experiments are taking place in
sites without cattle [37]. In addition, the research towards
the development of BCG-specific blood tests for cattle, and
the relatively short duration of BCG-induced reactivity in
livestock contribute to limit the concerns [126].
Further information regarding BCG biosafety is needed
to satisfy regulatory and licensing requirements for release
of oral bait vaccines to wildlife [82, 125]. Therefore, new
laboratory experiments will be conducted in order to assess
the potential oral or nasal excretion of BCG by vaccinated
wild boar. In addition, cattle will be exposed to BCG-
containing baits under controlled conditions to assess the
likeliness of developing a positive skin test. Other important
information regarding biosafety will be derived from the first
controlled field experiments starting soon in Southern Spain.
Furthermore, the recent development of an inactivated M.
bovis vaccine would significantly reduce the safety issues,
since no viable organisms are used [107].
10. Conclusions and Future ResearchDirections
During the last decade, research on TB epidemiology and
oral vaccine development and characterization in wild boar
allowed considering oral vaccination among available TB
control tools. The continued applied and basic research on
integrated TB control at the wildlife-livestock interface will
hopefully yield even more significant advances in the future.
Future research on TB vaccination in wild boar will
include both new controlled laboratory and field experi-
ments (Figure 2). Results obtained in experiments compar-
ing the eﬃcacy of inactivated M. bovis and BCG vaccines
encourage testing combinations of these vaccine prepara-
tions. The characterization of the immune mechanisms that
support protection against tuberculosis after vaccination
with BCG and inactivated vaccines are essential to advance
in the development of new improved vaccines and/or
vaccination schemes.
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Figure 2: Flowchart of the laboratory and field research and key results towards oral vaccination of Eurasian wild boar againstMycobacterium
bovis. Dashed boxes indicate future experiments.
A controlled and replicated experimental oral vaccina-
tion trial will start soon in southern Spain. The goals of
this first field trial are assessing the response of wild boar
to oral BCG and heat-killed M. bovis vaccination under
field conditions, gathering information on safety aspects
and analyzing the cost-eﬀectiveness of vaccination for TB
control in wild boar. This includes modeling the outcome of
vaccination as compared to population control.
Regarding models, preliminary data gathered from
individual-based models suggest that vaccinating piglets
over a long-term period has the potential to successfully
eradicate bTB from wild boar reservoirs in southern Spain.
Further research into the transmission rates between bTB
hosts and the eﬃcacy of the vaccine itself, but also on
the cost-eﬀectiveness of wild boar vaccination as compared
to population control (and their combinations) will add
important reinforcements to these initial findings.
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